UPDATE: MAY 26, 2017
Rocklage was recently interviewed by Ideamensch and it offered insight about his background and how the ideas of his business came to be. 5AM Ventures is his business that is based on science and life. For Dr. Rocklage, a typical day varies. Some of his days are spent researching untouched areas of life science and other days are spent working on his management portfolio. And when he’s not doing that, he is attending board meetings.
5AM Ventures is a seed as well as an early stage fund that aims at creating and developing biotechnology companies. The fund is usually sponsored by two among the top life science investment companies, Versant Ventures and Bay City Capital. They are managing more than $1 billion for the fund. It was in the year 2003 when it was announced that the fund had absorbed Scott M. Rocklage Ph.D. as a venture partner. Rocklage has been the CEO of Cubist Pharmaceuticals, Inc. since 1994 where he administered its development as well as the approval of Cubicin by the FDA to become an antibiotic treatment. He was also involved in the development of two other pharmaceutical products that were approved by FDA while working at Nycomed Salutar, Inc. as a CEO.
Scott Rocklage is expected to combine efforts with three other investment professionals at 5AM Ventures, Andy Schwab, John Diekman and Carin Mueller. The three founded the firm in the year 2002 just as a spin-out venture in Bay City Capital. Their first year of operation wasn’t a bad start because they managed to invest in six biotechnology companies. These include Ambrx, Kalypsys, Symyx Therapeutics, Celscia Therapeutics, Miikana, and Alexza.
John Diekman said that having Rocklage as an addition to the team was a tremendous achievement to 5AM Ventures in their first year of operation. Referring to his previous achievement in directing the approval of three NDAs and development of infrastructures for drug launches, Diekman believes he is a value addition to their existing business and their futures ventures.
“He has already become an Executive Chairman of Miikana Therapeutics, and we are close to finalizing another similar role in another portfolio company,” John Diekman said.
Dr. Rocklage and his new partners have known each other for over 15 years, and he was excited to join the team of investors and entrepreneurs. He added that he is willing to contribute the experience he gained over the years to ensure that 5AM Ventures grows its portfolio of inspiring biotechnology and innovation.
Dr. Rocklage has served in different pharmaceuticals companies holding executive positions. They include Cubist Pharmaceuticals, Nycomed Salutar, Inc., MDS Proteomics Inc., Nycomed Interventional Inc., Salutar, Inc., Miikana Therapeutics and Catalytica, Inc. Rocklage has also led different teams to raise funds to cater for various pharmaceutical operations such as in the first public offering of Cubist Pharmaceutical and other successful fundraising events. Through this, he has managed to raise over $500 million.
Scott Rocklage is a member of the board of the Massachusetts Biotechnology Council, affiliates of the Whitehead Institute as well as BIO Emerging Company Section. He graduated from the University of California and the Massachusetts Institute of Technology holding a B.S. in Chemistry and a Ph.D. in Chemistry respectively. 5AM Ventures has gained a tremendous growth over the years under his control and management.